Jaymin Kang

2 days ago | empr.com | Jaymin Kang

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) for the treatment of mucopolysaccharidosis II (MPS II), also known as Hunter syndrome. MPS II is a rare, X-linked recessive disorder caused by lysosomal iduronate-2-sulfatase (I2S) enzyme deficiency, leading to glycosaminoglycan accumulation and organ dysfunction.

2 days ago | clinicaladvisor.com | Jaymin Kang

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study. Icotrokinra is an investigational oral peptide that blocks the interleukin (IL)-23 receptor, which plays a significant role in the pathogenesis of plaque psoriasis and other IL-23 mediated diseases.

3 days ago | empr.com | Jaymin Kang

Topline data were announced from a phase 3 trial evaluating somapacitan in pre-pubertal children with growth disorders. Somapacitan is a human growth hormone analog currently marketed under the brand name Sogroya for the treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH), and for the replacement of endogenous GH in adults with GH deficiency.

6 days ago | empr.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved the Teal Wand™ for cervical cancer screening in women at average risk for the disease, aged 25 to 65 years. The Teal Wand is a prescription, vaginal self-collection device intended to test for 14 types of high-risk human papillomavirus (HPV) that have the highest risk for causing cervical cancer. The device provides an alternative option for women who prefer an at-home method of screening rather than an in-person pap smear.

6 days ago | empr.com | Jaymin Kang

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study. Icotrokinra is an investigational oral peptide that blocks the interleukin (IL)-23 receptor, which plays a significant role in the pathogenesis of plaque psoriasis and other IL-23 mediated diseases.